Clinical Trials | December 13, 2022
Moderna and Merck announce personalized mRNA cancer vaccine
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Acquisition expands Merck’s growing hematology portfolio
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Subscribe To Our Newsletter & Stay Updated
